Cigna Group (NYSE:CI) on Friday reported first-quarter 2025 revenue of $65.45 billion, beating analyst estimates of $60.39 billion.
Sales increased 14% year over year, reflecting the growth of existing client relationships and strong specialty pharmacy growth in Evernorth Health Services.
The company reported adjusted earnings of $6.74 per share, beating analysts’ estimates of $6.35.
Evernorth Health Services, including Pharmacy Benefit and Specialty and Care Services, reported first-quarter sales of $53.68 billion, up 16%.
Also Read: FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth’s PBMs Amid Commissioner Shortage
Cigna Healthcare segment sales increased 9% to $14.48 billion, primarily reflecting premium rate increases to cover expected increases in underlying medical costs.
Cigna ended the March quarter with total medical customers decreasing 6% from Dec. 31, 2024, to 18.04 million, primarily reflecting the impact of the HCSC transaction.
Total customer relationships stood at 182.2 million at March 31, 2025.
Total pharmacy customers as of March 31, 2025, increased 3% from Dec. 31, 2024, to 122.3 million due to new sales and the continued expansion of relationships.
“Our strong first quarter results and increase in outlook for full-year earnings reflects the strength of our Evernorth Health Services and Cigna Healthcare growth platforms in a dynamic environment,” said David Cordani, chairman and CEO of the Cigna Group.
Outlook: Cigna expects fiscal 2025 adjusted income per share of $29.60, up from $29.50 versus the consensus of $29.60
The company expects Evernorth’s adjusted income from operations (pre-tax of at least $7.2 billion, with at least $4.125 billion for Cigna Healthcare.
Cigna Healthcare Medical Care Ratio is expected to be between 83.2% to 84.2%.
CI Price Action: Cigna stock is up 2.93% at $344.99 during the premarket session at publication on Friday.
Read Next:
Photo: Shutterstock
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。